Read Books Online and Download eBooks, EPub, PDF, Mobi, Kindle, Text Full Free.
Egfr Directed Therapy In Lung Cancer
Download Egfr Directed Therapy In Lung Cancer full books in PDF, epub, and Kindle. Read online Egfr Directed Therapy In Lung Cancer ebook anywhere anytime directly on your device. Fast Download speed and no annoying ads. We cannot guarantee that every ebooks is available!
Book Synopsis EGFR-Directed Therapy in Lung Cancer by : So Yeon Kim
Download or read book EGFR-Directed Therapy in Lung Cancer written by So Yeon Kim and published by Cambridge University Press. This book was released on 2023-01-26 with total page 72 pages. Available in PDF, EPUB and Kindle. Book excerpt: Epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) is a clinically important driver alteration affecting approximately one-third of lung cancer patients. Treatments for EGFR-exon 19 deletion and exon 21 L858R NSCLC have evolved over the last decade from first-generation reversible tyrosine kinase inhibitors (TKI) to third-generation irreversible TKIs, of which osimertinib has been the widely accepted as first-line therapy. Despite survival improvement seen with osimertinib and its efficacy against acquired T790M mutation, resistance through on-target and off-target pathways eventually develop. This Element describes the structural biology and pathophysiology of EGFR-mutant NSCLC and discusses past, current, and future treatment options in the metastatic, neoadjuvant, and adjuvant settings. It describes the biology and recently approved treatment for EGFR-exon 20 insertion mutation and the treatment for the uncommon exon 18 (G719X), 20 (S768I), and 21 (L861Q) mutations. It also outlines the promising clinical applications of circulating tumor DNA (ctDNA).
Book Synopsis Targeted Therapies for Lung Cancer by : Ravi Salgia
Download or read book Targeted Therapies for Lung Cancer written by Ravi Salgia and published by Springer. This book was released on 2019-06-26 with total page 238 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book contextualizes translational research and provides an up to date progress report on therapies that are currently being targeted in lung cancer. It is now well established that there is tremendous heterogeneity among cancer cells both at the inter- and intra-tumoral level. Further, a growing body of work highlights the importance of targeted therapies and personalized medicine in treating cancer patients. In contrast to conventional therapies that are typically administered to the average patient regardless of the patient’s genotype, targeted therapies are tailored to patients with specific traits. Nonetheless, such genetic changes can be disease-specific and/or target specific; thus, the book addresses these issues manifested in the somatically acquired genetic changes of the targeted gene. Each chapter is written by a leading medical oncologist who specializes in thoracic oncology and is devoted to a particular target in a specific indication. Contributors provide an in-depth review of the literature covering the mechanisms underlying signaling, potential cross talk between the target and downstream signaling, and potential emergence of drug resistance.
Book Synopsis Targeted Therapies in Lung Cancer: Management Strategies for Nurses and Practitioners by : Marianne Davies
Download or read book Targeted Therapies in Lung Cancer: Management Strategies for Nurses and Practitioners written by Marianne Davies and published by Springer. This book was released on 2019-07-16 with total page 120 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book aims to educate nurses and advanced practice providers (APP’s) about known mutations, availability of targeted therapy and the management of patients with non-small cell lung cancer (NSCLC). It will educate nurses and practitioners about the scope of therapy to assure safe and effective lung cancer treatment. In this era of personalized medicine, nurses and APP’s are responsible for guiding patients from diagnosis through treatment. This starts with the identification of patients that can benefit from these therapies, the key role of biopsy acquisition (ie. what to test, when and how often) and treatment selection based on the mutation identified. Readers will learn about the mechanisms of action, administration, potential adverse side effects and unique management strategies for these targeted agents. Lung cancer continues to be the leading cause of cancer death in the United States and worldwide. Recent advances in the identification of specific oncogenic mutations that drive cancer development, growth and metastasis have led to major paradigm shifts in lung cancer treatment. Sophisticated methods are required to identify specific mutations at the time of diagnosis. This book explains how molecularly targeted therapies have been developed that target these drivers. To date, several tyrosine kinase inhibitors have been approved to target the epidermal growth factor receptor (EGFR), EML4-ALK ,ROS1 and BRAF. Most recently, immune checkpoint inhibitors have been approved with some indication that efficacy may be enhanced for patients who overexpress PD-L1. While some driver mutations have been identified, there is ongoing investigation into additional mutations. In the case of driver mutations, lung cancers will develop resistance to therapy. This book provides nurses and APP’s with the mechanisms of resistance that have been identified such as T790 mutation and many others in the EGFR mutation, and shows how the next level of drug development is focused on identifying mechanisms of resistance and development of new agents that overcome these mutations. With this book in hand, nurses and practitioners will be able to navigate patients through this ever expanding field of lung cancer treatment.
Book Synopsis Molecular Targeted Therapy of Lung Cancer by : Yuichi Takiguchi
Download or read book Molecular Targeted Therapy of Lung Cancer written by Yuichi Takiguchi and published by Springer. This book was released on 2017-01-24 with total page 321 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book discusses the latest molecular targeted therapy of lung cancer including its evaluation and future directions. It clearly illustrates the initial dramatic effectiveness of molecular targeted therapy, recurrence of the disease, overcoming the wide variety of resistance mechanisms using new-generation molecular targeted agents and potential novel approaches. It also outlines the increasing necessity for new diagnostic technology and strategies for managing different adverse effects and novel methods for evaluating effectiveness and safety. Edited and authored by opinion leaders, Molecular Targeted Therapy of Lung Cancer provides a comprehensive overview of the disease and its treatments. It is a valuable resource for graduate students, post-doctoral fellows and faculty staff, as well as researchers involved in clinical and translational research on lung cancer, helping promote new ideas for further advances.
Book Synopsis Guide to Targeted Therapies: EGFR mutations in NSCLC by : Federico Cappuzzo
Download or read book Guide to Targeted Therapies: EGFR mutations in NSCLC written by Federico Cappuzzo and published by Springer. This book was released on 2014-09-25 with total page 75 pages. Available in PDF, EPUB and Kindle. Book excerpt: Guide to Targeted Therapies: EGFR Mutations in NSCLC is a speedy and up-to-date review, which discusses EGFR mutations, testing methods and technology, current and emerging therapies, and resources that clinicians can provide to their patients. Busy healthcare professionals who want a quick review of EGFR gene mutations as well as a summary of current therapies will benefit from this succinct guide.
Book Synopsis Acquired Resistance to Targeted Therapy in EGFR-mutant Lung Adenocarcinoma by : Caroline Amalia Nebhan
Download or read book Acquired Resistance to Targeted Therapy in EGFR-mutant Lung Adenocarcinoma written by Caroline Amalia Nebhan and published by . This book was released on 2014 with total page 145 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Book Synopsis Second Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological and Molecular Aspects of Novel Promising Drugs by : Umberto Malapelle
Download or read book Second Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological and Molecular Aspects of Novel Promising Drugs written by Umberto Malapelle and published by Frontiers Media SA. This book was released on 2017-08-29 with total page 86 pages. Available in PDF, EPUB and Kindle. Book excerpt: Lung cancer still remains a challenging disease with a higher mortality rate in comparison to other cancers. The discovery of oncogene addicted tumours and targeted therapies responsive to these targets lead to a meaningful change in the prognosis of these diseases. Unfortunately, these newer therapeutic options are reserved to a minor part of lung cancer patients harbouring specific mutations. In the so called wild type population, the first line options bring the median overall survival to go beyond 1 year, and in the population receiving the maintenance therapy over 16 months. Given these results, more than 60% of patients may receive a second line therapy with further opportunities to improve the length and quality of life. For patients not harbouring targetable DNA mutations newer options will be available for second line therapeutic schemes and two major assets seem to be promising: immune modulation and anti-angiogenetic agents. In particular, anti PD1/PDL1 antibodies, VEGFR antibodies and TKIs, these latter combined with standard chemotherapy docetaxel advance the median overall survival of 12 months. These drugs have a different mechanism of action, various adverse events and their activity is different depending on the types of population. However, the biomarkers’ activity and efficacy prediction are not fully or totally understood. In addition, also for patients with DNA targetable mutations new drugs seems to be promising for the use in the second line therapeutic protocols. In particular, drugs selectively directed against ALK translocation and mutational events and EGFR T790M secondary mutations seems to be very promising. In this Research Topic we critically discuss the older therapies and the historical development of second line, putting in to perspective the new agents available in clinical practice. We discuss their importance from a clinical point of view, but also consider and exploit the complex molecular mechanisms responsible of their efficacy or of the subsequently observed resistance phenomena. In this perspective, the undercovering and characterization of novel predictive biomarkers by NGS technology, the characterization of novel actors in the signal transduction pathway modulating the response of the cells, the optimization of new diagnostic tool as the evaluation of liquid biopsy and the implementation of more suitable pre-clinical models are crucial aspects dissected too. Nivolumab, nintedanib and ramucirumab probably will give the opportunity to improve the efficacy outcomes for the treatment of wild type tumours in second line therapeutic schemes, but many aspects should be debated in order that these agents are made available to patients, planning ahead a therapeutic strategy, beginning from the first line therapy, to the subsequent ones in a logical and affordable manner. As well, for treatment of mutated tumours, mutated EGFR irreversible inhibitors such as rociletinib and AZD9291, and ALK targeting drugs ceritinib and alectinib will also play an important role in the immediate future. Probably the right way is to give all the available opportunities to patients, but challenges and pitfalls should be carefully debated, and by launching this Research Topic we tried to give some practical insights in this changing landscape.
Book Synopsis Advances in Systemic Therapy for Non-Small Cell Lung Cancer , An Issue of Thoracic Surgery Clinics by : Jessica Donington
Download or read book Advances in Systemic Therapy for Non-Small Cell Lung Cancer , An Issue of Thoracic Surgery Clinics written by Jessica Donington and published by Elsevier Health Sciences. This book was released on 2020-05-11 with total page 137 pages. Available in PDF, EPUB and Kindle. Book excerpt: This issue of Thoracic Surgery Clinics, guest edited by Drs. Jyoti Patel and Jessica Donington, is devoted to Advances in Systemic Therapy for Non-Small Cell Lung Cancer. Drs. Patel and Donington have assembled expert authors to review the following topics: Adjuvant and Neoadjuvant Immunotherapy; Combining Immunotherapy with Radiation in Lung Cancer; Adjuvant Chemotherapy; ALK Mutations; Molecular Targets Beyond the Big 3; Advances in Systemic Therapy; Liquid Biopsies in NSCLC; Combining Immunotherapy and Chemotherapy for NSCLC; ROS-1 Mutations; EGFR Mutations; and more!
Book Synopsis Therapeutic Strategies in EGFR Mutant Lung Cancer by : Yaxiong Zhang
Download or read book Therapeutic Strategies in EGFR Mutant Lung Cancer written by Yaxiong Zhang and published by Frontiers Media SA. This book was released on 2022-11-03 with total page 239 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Book Synopsis Update on the Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) in New Era of Personalised Medicine by : Vera Hirsh
Download or read book Update on the Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) in New Era of Personalised Medicine written by Vera Hirsh and published by Frontiers Media SA. This book was released on 2018-01-24 with total page 95 pages. Available in PDF, EPUB and Kindle. Book excerpt: Lung cancer remains a major cause of death in of both women and men in our society. Lung cancer treatment paradigms have changed enormously as we’ve started to understand the genetic complexity and the multiple driver mutations influencing the disease. Therapeutics directed towards, or to inhibit signaling pathways has resulted in increased life spans for our patients. Over the last two decades, we have gone from simple chemotherapy used to treat all, to a personalized medicine approach for the majority. For non-small cell lung cancer patients without driver mutations, the world of immune oncology has arrived. These improved long-term outcomes mean that now our lung cancer patients can live with their cancers, but without progression. The aim of this book is to catalogue the current state of knowledge for the many facets of advanced lung cancer. It describes current treatment approaches for driver mutations, rare mutations, and rare thoracic malignancies such as neuroendocrine tumors. Most importantly, this book addresses the topics of palliative treatment and care which allow our patients to enjoy longer survival with the highest quality of life. We hope you enjoy this e-book. The future is brighter for lung cancer patients and as lung cancer specialists; we finally feel sense optimism about treatment options for our patients.
Book Synopsis Overcoming Resistance to EGFR Inhibitors in EGFR-Mutant NSCLC by : Anthony Faber
Download or read book Overcoming Resistance to EGFR Inhibitors in EGFR-Mutant NSCLC written by Anthony Faber and published by Academic Press. This book was released on 2023-01-30 with total page 150 pages. Available in PDF, EPUB and Kindle. Book excerpt: Overcoming Resistance to EGFR Inhibitors in EGFR Mutant NSCLC presents updated information on how EGFR mutant lung cancers evolve to evade EGFR inhibitors, clinical strategies that identify these mechanisms, and how to implement newer therapeutic strategies to combat resistance and improve patient survival. As resistance to EGFR inhibitors is often through re-activation of MEK/ERK and PI3K pathways, or through loss of cell death responses, there is much overlap with resistance to targeted therapies in other paradigms, such as BRAF inhibitors in BRAF mutant melanoma, and HER2 inhibitors in HER2 amplified breast cancer. This book is a valuable resource for cancer researchers, clinicians, graduate students and other members of the biomedical field who are interested in promising treatments for lung cancer. - Presents historical context on how NSCLC and SCLC has been treated, with an emphasis on NSCLC and how the concept of EGFR inhibitors has been implemented - Discusses critical resistant mechanisms seen in the clinic to 1st, 2nd and 3rd generation EGFR inhibitors - Encompasses the current state of affairs in clinical trials to address resistance
Book Synopsis Molecular Pathology of Lung Cancer by : Philip T. Cagle
Download or read book Molecular Pathology of Lung Cancer written by Philip T. Cagle and published by Springer Science & Business Media. This book was released on 2012-06-14 with total page 217 pages. Available in PDF, EPUB and Kindle. Book excerpt: As with other books in the Molecular Pathology Library Series, Molecular Pathology of Lung Cancer bridges the gap between the molecular specialist and the clinical practitioner, including the surgical pathologist who now has a key role in decisions regarding molecular targeted therapy for lung cancer. Molecular Pathology of Lung Cancer provides the latest information and current insights into the molecular basis for lung cancer, including precursor and preinvasive lesions, molecular diagnosis, molecular targeted therapy, molecular prognosis, molecular radiology and related fields for lung cancer generally and for the specific cell types. As many fundamental concepts about lung cancer have undergone revision in only the past few years, this book will likely be the first to comprehensively cover the new molecular pathology of lung cancer. It provides a foundation in this field for pathologists, medical oncologists, radiation oncologists, thoracic surgeons, thoracic radiologists and their trainees, physician assistants, and nursing staff.
Book Synopsis Lung Cancer E-Book by : Erin Alexis Gillaspie
Download or read book Lung Cancer E-Book written by Erin Alexis Gillaspie and published by Elsevier Health Sciences. This book was released on 2023-08-24 with total page 355 pages. Available in PDF, EPUB and Kindle. Book excerpt: Care of the lung cancer patient—screening, diagnosis, and treatment—has undergone recent dramatic changes due to technologic and research-driven advances. Lung Cancer: An Evidence-Based Approach to Multidisciplinary Management covers every aspect of this fast-changing field, including new screening guidelines, new practice standards, and new treatment advances that have led to higher survival rates. This practical, clinically oriented resource provides thorough, evidence-based coverage from experts in the field, including the increasingly important precision medicine approach in lung cancer planning and management. - Discusses key topics such as small cell and non-small cell lung cancers; immunotherapy, molecular cohorts including ROS1, BRAF, HER2, Met, and NTRK; oligometastatic disease; and more. - Covers individualized treatment plans for chemotherapy, radiotherapy, targeted biomarker-derived therapies, and new and emerging immunotherapies. - Provides excellent visual guidance throughout, including algorithms, pathology specimens, anatomic drawings, and PET/CT and CT imaging for diagnosis and treatment planning. - Features "Top 5 Clinical Pearls at the beginning of each chapter. - Shares the experience and knowledge of medical oncologists, radiation oncologists, surgical oncologists, and thoracic radiologists for a real-world tumor board perspective.
Book Synopsis Fast Facts: Non-Small-Cell Lung Cancer by : M. O'Brien
Download or read book Fast Facts: Non-Small-Cell Lung Cancer written by M. O'Brien and published by Karger Medical and Scientific Publishers. This book was released on 2022-03-16 with total page 148 pages. Available in PDF, EPUB and Kindle. Book excerpt: Despite an overall decrease in tobacco use, lung cancer (80–85% of which is non-small-cell lung cancer [NSCLC]) is still the leading cause of cancer death in both men and women worldwide. Annual low-dose CT screening of high-risk individuals has the potential to detect early-stage tumors, which can usually be successfully treated with a combination of surgery, radiotherapy, and chemotherapy and, in some cases, targeted therapy. However, most patients with NSCLC still present with advanced or metastatic disease. For these patients, initial therapy is guided by the tumor’s molecular characteristics and patient’s performance status. Targeted therapies have significantly improved clinical outcomes and, for some patients with no targetable genetic alterations, immunotherapy has demonstrated significant overall survival benefit. This insightful guide is designed to bring you up to speed with the latest developments and is important reading for all health professionals and medical trainees working in this fast-moving field. Table of Contents: • Prevention and screening • Diagnosis and staging • Surgery • Radiotherapy • Systemic therapy in non-metastatic NSCLC • Systemic therapy in advanced-stage/metastatic disease without a molecular driver • Personalized treatment in advanced NSCLC • Oligometastatic disease and brain metastases
Book Synopsis Guide to Targeted Therapies: Treatment Resistance in Lung Cancer by : Federico Cappuzzo
Download or read book Guide to Targeted Therapies: Treatment Resistance in Lung Cancer written by Federico Cappuzzo and published by Springer. This book was released on 2015-10-15 with total page 71 pages. Available in PDF, EPUB and Kindle. Book excerpt: This text is a concise and up-to-date review, which discusses the background, development and mechanisms of resistance, testing methods and technology, current and emerging therapies and resources that clinicians can provide to their patients. Busy healthcare professionals who want a quick review of treatment resistance in lung cancer as well as a summary of current therapies will benefit from this succinct guide.
Book Synopsis Study of Molecular Mechanisms of Sensitivity and Resistance to EGFR-Targeted Therapy in Lung Cancer by : Zhenfeng Zhang
Download or read book Study of Molecular Mechanisms of Sensitivity and Resistance to EGFR-Targeted Therapy in Lung Cancer written by Zhenfeng Zhang and published by . This book was released on 2010 with total page 143 pages. Available in PDF, EPUB and Kindle. Book excerpt: Lung cancer is still the leading cause of cancer-related death worldwide. EGFR-targeted tyrosine kinase inhibitors (TKI), such as erlotinib and gefitinib, have dramatic clinical effects on EGFR-dependent lung cancers and are used as first-line therapy for patients with EGFR-mutant lung tumors. However, eventually all tumors acquire secondary resistance to the drugs and progress. Sensitivity to such EGFR-TKI is determined by activating mutations in EGFR tyrosine kinase domain whereas resistance to the TKI can be conferred by EGFR secondary mutations such as EGFR T790M and MET activation. Using a T790M-mutant H1975 NSCLC cell line which is gefitinib-resistant but sensitive to an irreversible EGFR inhibitor CL-387,785 allowed us to compare the target gene changes by treatment with gefitinib or CL387,785 in a transcriptional profiling study. We identified several dual specificity phosphatases (DUSPs) among the most highly and immediately regulated genes upon EGFR inhibition. DUSPs act as natural terminators of MAPK signal transduction and we demonstrate a tumor suppressive role of DUSP6 via targeting ERK activity. We also show that the regulation of DUSP6 is mediated at the promoter level by ETS1, a well-known nuclear target of activated ERK, indicating an important negative feedback loop in NSCLC. Furthermore, we developed an erlotinib-resistant NSCLC cell model and explored mechanisms of such resistance. We discover a novel mechanism of erlotinib resistance involving overexpression of AXL. Further studies confirm that co-treatment using erlotinib along with AXL knockdown or pharmacological inhibition resensitizes these resistant cells leading to cell death. These results suggest that an oncogenic switch from EGFR-dependent to EGFR/AXL-codependent signaling can lead to secondary EGFR-TKI resistance in NSCLC. In summary, our findings provide novel options for the improved targeting of EGFR-dependent tumors by the identification of DUSP6 and AXL as important modulators of EGFR sensitivity/resistance.
Book Synopsis IASLC Atlas of ALK and ROS1 Testing in Lung Cancer by : Ming Sound Tsao
Download or read book IASLC Atlas of ALK and ROS1 Testing in Lung Cancer written by Ming Sound Tsao and published by . This book was released on 2016-12-04 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt: The IASLC Atlas of ALK and ROS1 Testing in Lung Cancer is a resource designed to help pathologists, laboratory scientists, and practicing physicians better understand the background, protocol, and interpretation of results of ALK and ROS1 testing for patients with advanced non-small cell lung cancer.
